One of these products, L19-IL2 is currently being evaluated in phase II clinical trials as single immunostimulatory agent [NCT02957019] and phase III in combination with targeted TNF for the of patients with fully resectable stage IIIB, C melanoma [NCT02938299]. The gene discussed is TNF; the disease is melanoma.